Date: Mar 30th, 2022

Your Name: Takahiro Suzuki

Manuscript Title: Double stapling method for closure of intraoperative alveolar air leakage adjacent to

the staple line: a randomized experimental study on ex vivo porcine lungs

Manuscript number (if known): Unknown

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial plan	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time trame. Since the initial plan	ining of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past 36 m	nonths
2	Grants or contracts from any entity (if not indicated in item #1 above).	Eli Lilly Japan K.K. Shionogi & Co., Ltd. Taiho Pharmaceutical Co., Ltd. Chugai Pharmaceutical Co., Ltd. Daiichi Sankyo Co., Ltd. Kyowa Kirin Co., Ltd. Ethicon, Inc. Covidien Japan Inc.	Scholarship donation has been received from these companies to our institution.
3	Royalties or licenses	XNone	

4	Consulting force	V. Nana	
4	Consulting fees	XNone	
5	Payment or honoraria for	X None	
•	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
-	6	V N	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

Our institution received scholarship donation from Eli Lilly Japan K.K., Shionogi & Co., Ltd., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Kyowa Kirin Co., Ltd., Ethicon, Inc., and Covidien Japan Inc.. This study was funded by the institutional research support grant. The funder had no role in the study design, analysis, and reporting of the study.

Please place an "X" next to the following statement to indicate your agreement:

Date: Mar 30th, 2022

Your Name: Keisuke Asakura

Manuscript Title: Double stapling method for closure of intraoperative alveolar air leakage adjacent to

the staple line: a randomized experimental study on ex vivo porcine lungs

Manuscript number (if known): Unknown

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom	Specifications/Comments
		you have this relationship or	(e.g., if payments were made to you or to your institution)
		indicate none (add rows as needed)	institution)
		Time frame: Since the initial plan	ning of the work
1	All support for the present	X None	
1	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time limit for this item.		
		Time frame: past 36 m	nonths
2	Grants or contracts from	Eli Lilly Japan K.K.	Scholarship donation has been received from these
	any entity (if not indicated	Shionogi & Co., Ltd.	companies to our institution.
	in item #1 above).	Taiho Pharmaceutical Co., Ltd.	
		Chugai Pharmaceutical Co., Ltd.	
		Daiichi Sankyo Co., Ltd.	
		Kyowa Kirin Co., Ltd.	
		Ethicon, Inc.	
		Covidien Japan Inc.	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
_			
5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

Our institution received scholarship donation from Eli Lilly Japan K.K., Shionogi & Co., Ltd., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Kyowa Kirin Co., Ltd., Ethicon, Inc., and Covidien Japan Inc.. This study was funded by the institutional research support grant. The funder had no role in the study design, analysis, and reporting of the study.

Please place an "X" next to the following statement to indicate your agreement:

Date: Mar 30th, 2022

Your Name: Takumi Egawa

Manuscript Title: Double stapling method for closure of intraoperative alveolar air leakage adjacent to

the staple line: a randomized experimental study on ex vivo porcine lungs

Manuscript number (if known): Unknown

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom	Specifications/Comments
		you have this relationship or	(e.g., if payments were made to you or to your institution)
		indicate none (add rows as needed)	institution)
		Time frame: Since the initial plan	ning of the work
1	All support for the present	X None	
1	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time limit for this item.		
		Time frame: past 36 m	nonths
2	Grants or contracts from	Eli Lilly Japan K.K.	Scholarship donation has been received from these
	any entity (if not indicated	Shionogi & Co., Ltd.	companies to our institution.
	in item #1 above).	Taiho Pharmaceutical Co., Ltd.	
		Chugai Pharmaceutical Co., Ltd.	
		Daiichi Sankyo Co., Ltd.	
		Kyowa Kirin Co., Ltd.	
		Ethicon, Inc.	
		Covidien Japan Inc.	
3	Royalties or licenses	XNone	

4	Consulting force	V. Nana	
4	Consulting fees	XNone	
5	Payment or honoraria for	X None	
•	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
-	6	V N	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

Our institution received scholarship donation from Eli Lilly Japan K.K., Shionogi & Co., Ltd., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Kyowa Kirin Co., Ltd., Ethicon, Inc., and Covidien Japan Inc.. This study was funded by the institutional research support grant. The funder had no role in the study design, analysis, and reporting of the study.

Please place an "X" next to the following statement to indicate your agreement:

Date: Mar 30th, 2022

Your Name: Masahiro Kawauchi

Manuscript Title: Double stapling method for closure of intraoperative alveolar air leakage adjacent to

the staple line: a randomized experimental study on ex vivo porcine lungs

Manuscript number (if known): Unknown

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial plan	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time trame: Since the initial plan	ining of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past 36 m	nonths
2	Grants or contracts from any entity (if not indicated in item #1 above).	Eli Lilly Japan K.K. Shionogi & Co., Ltd. Taiho Pharmaceutical Co., Ltd. Chugai Pharmaceutical Co., Ltd. Daiichi Sankyo Co., Ltd. Kyowa Kirin Co., Ltd. Ethicon, Inc. Covidien Japan Inc.	Scholarship donation has been received from these companies to our institution.
3	Royalties or licenses	XNone	

4	Consulting force	V. Nana	
4	Consulting fees	XNone	
5	Payment or honoraria for	X None	
•	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
-	6	V N	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

Our institution received scholarship donation from Eli Lilly Japan K.K., Shionogi & Co., Ltd., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Kyowa Kirin Co., Ltd., Ethicon, Inc., and Covidien Japan Inc.. This study was funded by the institutional research support grant. The funder had no role in the study design, analysis, and reporting of the study.

Please place an "X" next to the following statement to indicate your agreement:

Date: Mar 30th, 2022 Your Name: Yu Okubo

Manuscript Title: Double stapling method for closure of intraoperative alveolar air leakage adjacent to

the staple line: a randomized experimental study on ex vivo porcine lungs

Manuscript number (if known): Unknown

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial plan	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time trame. Since the initial plan	ining of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past 36 m	nonths
2	Grants or contracts from any entity (if not indicated in item #1 above).	Eli Lilly Japan K.K. Shionogi & Co., Ltd. Taiho Pharmaceutical Co., Ltd. Chugai Pharmaceutical Co., Ltd. Daiichi Sankyo Co., Ltd. Kyowa Kirin Co., Ltd. Ethicon, Inc. Covidien Japan Inc.	Scholarship donation has been received from these companies to our institution.
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
_			
5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

Our institution received scholarship donation from Eli Lilly Japan K.K., Shionogi & Co., Ltd., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Kyowa Kirin Co., Ltd., Ethicon, Inc., and Covidien Japan Inc.. This study was funded by the institutional research support grant. The funder had no role in the study design, analysis, and reporting of the study.

Please place an "X" next to the following statement to indicate your agreement:

Date: Mar 30th, 2022 Your Name: Kyohei Masai

Manuscript Title: Double stapling method for closure of intraoperative alveolar air leakage adjacent to

the staple line: a randomized experimental study on ex vivo porcine lungs

Manuscript number (if known): Unknown

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial plan	Specifications/Comments (e.g., if payments were made to you or to your institution) ning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past 36 m	onths
2	Grants or contracts from any entity (if not indicated in item #1 above).	Eli Lilly Japan K.K. Shionogi & Co., Ltd. Taiho Pharmaceutical Co., Ltd. Chugai Pharmaceutical Co., Ltd. Daiichi Sankyo Co., Ltd. Kyowa Kirin Co., Ltd. Ethicon, Inc. Covidien Japan Inc.	Scholarship donation has been received from these companies to our institution.
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
_			
5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

Our institution received scholarship donation from Eli Lilly Japan K.K., Shionogi & Co., Ltd., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Kyowa Kirin Co., Ltd., Ethicon, Inc., and Covidien Japan Inc.. This study was funded by the institutional research support grant. The funder had no role in the study design, analysis, and reporting of the study.

Please place an "X" next to the following statement to indicate your agreement:

Date: Mar 30th, 2022 Your Name: Kaoru Kaseda

Manuscript Title: Double stapling method for closure of intraoperative alveolar air leakage adjacent to

the staple line: a randomized experimental study on ex vivo porcine lungs

Manuscript number (if known): Unknown

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial plan	ning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past 36 m	onths
2	Grants or contracts from	Eli Lilly Japan K.K.	Scholarship donation has been received from these
	any entity (if not indicated	Shionogi & Co., Ltd.	companies to our institution.
	in item #1 above).	Taiho Pharmaceutical Co., Ltd.	
		Chugai Pharmaceutical Co., Ltd.	
		Daiichi Sankyo Co., Ltd.	
		Kyowa Kirin Co., Ltd.	
		Ethicon, Inc.	
		Covidien Japan Inc.	
3	Royalties or licenses	X None	

4	Consulting force	V. Nana	
4	Consulting fees	XNone	
5	Payment or honoraria for	X None	
•	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
-	6	V N	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

Our institution received scholarship donation from Eli Lilly Japan K.K., Shionogi & Co., Ltd., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Kyowa Kirin Co., Ltd., Ethicon, Inc., and Covidien Japan Inc.. This study was funded by the institutional research support grant. The funder had no role in the study design, analysis, and reporting of the study.

Please place an "X" next to the following statement to indicate your agreement:

Date: Mar 30th, 2022

Your Name: Tomoyuki Hishida

Manuscript Title: Double stapling method for closure of intraoperative alveolar air leakage adjacent to

the staple line: a randomized experimental study on ex vivo porcine lungs

Manuscript number (if known): Unknown

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial plan	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time trame: Since the initial plan	ming of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past 36 m	onths
2	Grants or contracts from any entity (if not indicated in item #1 above).	Eli Lilly Japan K.K. Shionogi & Co., Ltd. Taiho Pharmaceutical Co., Ltd. Chugai Pharmaceutical Co., Ltd. Daiichi Sankyo Co., Ltd. Kyowa Kirin Co., Ltd. Ethicon, Inc. Covidien Japan Inc.	Scholarship donation has been received from these companies to our institution.
3	Royalties or licenses	XNone	

4	Consulting force	V. Nana	
4	Consulting fees	XNone	
5	Payment or honoraria for	X None	
•	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
-	6	V N	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

Our institution received scholarship donation from Eli Lilly Japan K.K., Shionogi & Co., Ltd., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Kyowa Kirin Co., Ltd., Ethicon, Inc., and Covidien Japan Inc.. This study was funded by the institutional research support grant. The funder had no role in the study design, analysis, and reporting of the study.

Please place an "X" next to the following statement to indicate your agreement:

Date: Mar 30th, 2022

Your Name: Hisao Asamura

Manuscript Title: Double stapling method for closure of intraoperative alveolar air leakage adjacent to

the staple line: a randomized experimental study on ex vivo porcine lungs

Manuscript number (if known): Unknown

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial plan	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time trame: Since the initial plan	ming of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past 36 m	onths
2	Grants or contracts from any entity (if not indicated in item #1 above).	Eli Lilly Japan K.K. Shionogi & Co., Ltd. Taiho Pharmaceutical Co., Ltd. Chugai Pharmaceutical Co., Ltd. Daiichi Sankyo Co., Ltd. Kyowa Kirin Co., Ltd. Ethicon, Inc. Covidien Japan Inc.	Scholarship donation has been received from these companies to our institution.
3	Royalties or licenses	XNone	

4	Consulting force	V. Nana	
4	Consulting fees	XNone	
5	Payment or honoraria for	X None	
•	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
-	6	V N	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

Our institution received scholarship donation from Eli Lilly Japan K.K., Shionogi & Co., Ltd., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Kyowa Kirin Co., Ltd., Ethicon, Inc., and Covidien Japan Inc.. This study was funded by the institutional research support grant. The funder had no role in the study design, analysis, and reporting of the study.

Please place an "X" next to the following statement to indicate your agreement: